Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Can brain dysfunction be a predisposing factor for metabolic syndrome?

Ram B Singh1, Daniel Pella, Viola Mechirova

  • 1Medical Hospital and Research Center, Moradabad, Subharti Medical College, Meerut/UP, India. icn2005@mickyonline.com

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|March 10, 2005
PubMed
Summary

Brain dysfunction and metabolic syndrome (MS) are linked by neurotransmitter imbalances and long-chain polyunsaturated fatty acid (PUFA) deficiencies. Omega-3 fatty acid supplementation may protect against MS, type 2 diabetes, and cardiovascular disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vericiguat: The Fifth Pillar of Heart Failure.

Reviews in cardiovascular medicine·2026
Same author

Sustainable diets and functional foods for the prevention of cardio-metabolic diseases and sustainable development goals of the UNO. An international consensus of scientific statement of the international college of nutrition and 28th world congress on clinical nutrition, Bogor, Indonesia.

BMC cardiovascular disorders·2026
Same author

Comprehensive Evaluation of Coronary Pathophysiology in the Context of COVID-19: Clinical Insights and Angiographic Assessment.

La Clinica terapeutica·2026
Same author

Evolocumab in Patients With High-Risk Diabetes: Results From the VESALIUS-CV Trial.

Diabetes care·2026
Same author

Clinical characteristics and management of hyperlipoproteinemia in patients with chronic coronary heart disease in Slovakia.

Archives of medical science : AMS·2025
Same author

The European Program for Prevention (EPP) - Implementing Proven Preventing Measures Now!

Global heart·2025

Area of Science:

  • Neuroscience
  • Metabolic Disorders
  • Nutritional Science

Background:

  • Metabolic syndrome (MS) is linked to cardiovascular disease and type 2 diabetes.
  • Brain dysfunction is increasingly recognized as a factor in MS pathogenesis.
  • Dietary factors and lifestyle influence neurotransmitter balance and brain function.

Purpose of the Study:

  • To review mechanisms linking brain dysfunction to metabolic syndrome (MS) pathogenesis.
  • To explore the role of nutrition, particularly long-chain polyunsaturated fatty acids (PUFAs), in MS.
  • To assess potential therapeutic interventions for MS targeting brain function.

Main Methods:

  • Systematic literature review of Medline articles up to September 2003.
  • Consultation with experts in the field.

Related Experiment Videos

  • Analysis of experimental studies on animal models of hypothalamic dysfunction.

    • Main Results:

    • Dietary factors (fat intake, PUFAs), stress, and sedentary behavior can alter neurotransmitter secretion (catecholamine, cortisol, serotonin) and sympathetic activity, contributing to MS.
    • Deficiency in long-chain PUFAs, especially omega-3 fatty acids, may damage brain neurons and insulin receptors, particularly during critical developmental periods.
    • Experimental models show ventromedial hypothalamus lesions induce insulin resistance and glucose intolerance, responsive to neurotransmitter modulation and insulin treatment.

    Conclusions:

    • Dysfunction in the ventromedial hypothalamus, influenced by neurotransmitters and PUFA status, can lead to metabolic abnormalities consistent with MS.
    • Supplementation with omega-3 fatty acids, alongside other interventions like meditation and certain medications, may offer protective or therapeutic benefits for MS and related conditions.
    • While a precise pathophysiological link is still under investigation, evidence supports n-3 fatty acid treatment for preventing type 2 diabetes, hypertension, and cardiovascular disease.